SLC34A2-ROS1/BaF3-南京科佰生物科技有限公司

產(chǎn)品搜索

產(chǎn)品分類

聯(lián)系我們

聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73191SLC34A2-ROS1/BaF3

名稱	SLC34A2-ROS1/BaF3
型號	CBP73191
報價
特點	SLC34A2-ROS1/BaF3,母細(xì)胞：BaF3，凍存條件：90% FBS+10% DMSO；

詳細(xì)內(nèi)容

CBP73191
I. Introduction
Cell Line Name：	SLC34A2-ROS1/BaF3
Host Cell:	Ba/F3
Stability:	16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)
Application:	Anti-proliferation assay and PD assay
Freeze Medium:	90% FBS+10% DMSO
Complete Culture Medium:	RPMI-1640+10%FBS
Mycoplasma Status:	Negative

II.Background
Approximately 2% of lung tumors harbor ROS1 fusions (Bergethon et al. 2012). Like ALK fusions, ROS1 fusions are more commonly found in light smokers (<10 pack years) and/or never-smokers. ROS1 fusions are also associated with younger age and adenocarcinomas (Bergethon et al. 2012). In preclinical models, ROS1 fusions are associated with sensitivity to tyrosine kinase inhibitors that have 'off-target' activity against ROS1, such as crizotinib (Bergethon et al. 2012; Davies et al. 2012). In addition, two patients—a previously treated metastatic NSCLC patient and a 65-year-old never smoker NSCLC patient—with tumors harboring ROS1 fusions have had partial responses to crizotinib (Bergethon et al. 2012; Davies et al. 2012). In an expansion cohort of a phase I study, 50 patients with ROS1-positive NSCLC demonstrated a 72% response rate and 19.2-month median progression-free survival interval when treated with crizotinib (Ou et al. 2013; Shaw et al. 2014). In a European case study, 32 ROS1-positive NSCLC cases treated with crizotinib were retrospectively reviewed, and an 80% response rate and a 9.1-month median progression-free survival interval was calculated in this cohort (Mazières et al. 2015). Several different ROS1 rearrangements have been described in NSCLC. These include SLC34A2-ROS1, CD74-ROS1, EZR-ROS1, TPM3-ROS1, and SDC4-ROS1 (Figure 1; Davies et al. 2012; Rikova et al. 2007; Takeuchi et al. 2012). Clinically, the presence of a ROS1 rearrangement is detected by fluorescence in situ hybridization (FISH) with a ROS1 breakapart probe. FISH testing is not able to discern which particular ROS1 fusion is found in a clinical sample. ROS1 rearrangements are non-overlapping with other oncogenic mutations found in NSCLC (e.g., EGFR mutations, KRAS mutations, ALK fusions, etc.; Bergethon et al. 2012).

III. Representative Data
1. WB of SLC34A2-ROS1 expression



2.Sanger Sequencing of SLC34A2-ROS1 Fusion
2. Anti-proliferation assay
Figure 3. Anti-proliferation assay of two reference compounds on the SLC34A2-ROS1/BaF3 Stable Cell Line.